We are proud to announce NearWave, a University of Notre Dame startup has been accepted into Y Combinator, the top accelerator in the world.
Y Combinator provides seed funding for startups in the early stage. It pays the startup expenses while they are getting started. The goal for Y Combinator is to get startups through the first phase so they can build something impressive enough to raise money on a larger scale. Getting into Y Combinator is the “stamp of approval” for startups. It gives startups a level of credibility.
This is the first year Y Combinator is investing $500,000 in each company.
NearWave helps doctors determine the best treatment path in pre-surgery breast cancer in just one week, rather than waiting the typical 3-6 months. The handheld imaging device allows those doctors to visualize treatment response for the 100,000 patients per year in the US receiving pre-surgery therapy, saving each patient months of toxic side effects during ineffective treatment.
Founders Roy Stillwell and Thomas O’Sullivan developed NearWave in the electrical engineering labs at Notre Dame.
NearWave is one of the IDEA Center’s “high potential startups.” High potential startups are companies that are more likely to scale and grow quickly compared to other companies.
In addition, the company has just taken the top prize at the asu.io pitch competition that came with a $100,000 non-dilutive grant.
To connect with Roy Stillwell use the following email: email: firstname.lastname@example.org